423 General Discussion 58. Linkens AEMJH, Milosevic V, van der Kuy PHM, Damen-Hendriks VH, Mestres Gonzalvo C, Hurkens KPGM. Medication-related hospital admissions and readmissions in older patients: an overview of literature. Int J Clin Pharm 2020;42:1243–51. https://doi. org/10.1007/s11096-020-01040-1. 59. Thevelin S, Spinewine A, Beuscart JB, Boland B, Marien S, Vaillant F, et al. Development of a standardized chart review method to identify drug-related hospital admissions in older people. Br J Clin Pharmacol 2018. https://doi.org/10.1111/bcp.13716. 60. Zerah L, Henrard S, Thevelin S, Feller M, Meyer-masseti C, Knol W, et al. Performance of a trigger tool for detecting drug-related hospital admissions in older people : analysis from the OPERAM trial 2021;716:1–13. 61. Schaefer JK, Errickson J, Li Y, Kong X, Alexandris-Souphis T, Ali MA, et al. Adverse Events Associated with the Addition of Aspirin to Direct Oral Anticoagulant Therapy without a Clear Indication. JAMA Intern Med 2021;181:817–24. https://doi.org/10.1001/ jamainternmed.2021.1197. 62. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009. https://doi.org/10.1001/archinternmed.2009.357. 63. Violan C, Foguet-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, et al. Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. PLoS One 2014;9:3–11. https://doi.org/10.1371/journal. pone.0102149. 64. Beuscart J, Knol W, Cullinan S, Schneider C, Dalleur O, Boland B, et al. International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med 2018;21:1–9. https://doi.org/10.1186/s12916-018-1007-9. 65. O’Mahony D, Gudmundsson A, Soiza RL, Petrovic M, Jose Cruz-Jentoft A, Cherubini A, et al. Prevention of adverse drug reactions in hospitalized older patients with multimorbidity and polypharmacy: the SENATOR* randomized controlled clinical trial. Age Ageing 2020;49:605–14. https://doi.org/10.1093/ageing/afaa072. 66. Verdoorn S, Kwint HF, Blom JW, Gussekloo J, Bouvy ML. Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMER-study). PLoS Med 2019;16:1–18. https://doi.org/10.1371/journal.pmed.1002798. 67. Mangin D, Lamarche L, Agarwal G, Banh HL, Dore Brown N, Cassels A, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials 2021;22:1–15. https://doi.org/10.1186/s13063-021-05685-9. 68. Vonk RAA, Hilderink HBM, Plasmans MHD, Kommer GJ, Polder JJ. Toekomstverkenning zorguitgaven 2015-2060 : Kwantitatief vooronderzoek in opdracht van de Wetenschappelijke Raad voor het Regeringsbeleid (WRR). Deel 1: toekomstprojecties. Heal Care Expend Foresight 2015-2060 Quant Prelim Study Req Sci Counc Gov Policy (WRR) Part 1 Futur Proj 2020. 69. Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: The GerontoNet ADR risk score. Arch Intern Med 2010;170:1142–8. https://doi.org/10.1001/archinternmed.2010.153. 70. Petrovic M, Van Der Cammen T, Onder G. Adverse drug reactions in older people: Detection and prevention. Drugs and Aging 2012;29:453–62. https://doi. org/10.2165/11631760-000000000-00000. 5
RkJQdWJsaXNoZXIy MTk4NDMw